Wall Street analysts expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will report earnings per share of ($0.46) for the current quarter, Zacks reports. Four analysts have provided estimates for Intellia Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.15). Intellia Therapeutics posted earnings of ($0.44) per share in the same quarter last year, which indicates a negative year over year growth rate of 4.5%. The business is expected to issue its next earnings report on Tuesday, October 30th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($1.97) per share for the current year, with EPS estimates ranging from ($2.25) to ($1.56). For the next year, analysts forecast that the business will report earnings of ($2.52) per share, with EPS estimates ranging from ($3.15) to ($1.94). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, August 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $6.39 million. During the same quarter in the previous year, the company earned ($0.45) earnings per share. The company’s revenue for the quarter was up 30.2% compared to the same quarter last year.
A number of equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Saturday, August 4th. BidaskClub cut shares of Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 26th. Cann reiterated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, May 1st. TheStreet cut shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Monday, May 7th. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Intellia Therapeutics in a research report on Friday, May 18th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Intellia Therapeutics presently has an average rating of “Buy” and a consensus price target of $34.14.
Shares of Intellia Therapeutics traded up $0.18, reaching $27.67, during mid-day trading on Friday, MarketBeat reports. The stock had a trading volume of 404,637 shares, compared to its average volume of 665,178. Intellia Therapeutics has a 52-week low of $15.06 and a 52-week high of $35.99. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -14.72 and a beta of 2.93.
In other news, Director Jean Francois Formela sold 6,686 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $25.04, for a total value of $167,417.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John M. Leonard sold 8,400 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,458 shares of company stock worth $764,361. Corporate insiders own 12.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. TIAA CREF Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 5.4% in the fourth quarter. TIAA CREF Investment Management LLC now owns 40,415 shares of the company’s stock worth $777,000 after buying an additional 2,076 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after buying an additional 2,333 shares in the last quarter. D.A. Davidson & CO. lifted its stake in shares of Intellia Therapeutics by 14.2% in the first quarter. D.A. Davidson & CO. now owns 19,219 shares of the company’s stock worth $405,000 after buying an additional 2,395 shares in the last quarter. Great West Life Assurance Co. Can lifted its position in Intellia Therapeutics by 2.5% during the second quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock valued at $2,652,000 after purchasing an additional 2,395 shares during the period. Finally, TRUE Private Wealth Advisors lifted its position in Intellia Therapeutics by 23.5% during the second quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock valued at $363,000 after purchasing an additional 2,533 shares during the period. Hedge funds and other institutional investors own 59.81% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Recommended Story: Why Dividend Stocks May Be Right for You
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.